Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 05

1593P - Real-world data on anemia management in patients with solid tumors and malignant lymphoma in Germany

Date

10 Sep 2022

Session

Poster session 05

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Hartmut Link

Citation

Annals of Oncology (2022) 33 (suppl_7): S713-S742. 10.1016/annonc/annonc1075

Authors

H. Link1, M. Kerkmann2, L. Holtmann2

Author affiliations

  • 1 Hematology, Medical Oncology, Private Practice - Dr. Hartmut Link, 67661 - Kaiserslautern/DE
  • 2 Mmf Gmbh, MMF Münster, 48155 - Münster/DE
More

Abstract 1593P

Background

Anemia is a frequent complication in patients with breast cancer (BC), gastrointestinal tumors (GC), lung cancer (LC) and malignant lymphomas (ML). Guidelines (GL) on anemia management (ESMO, DGHO) provide dedicated algorithms for diagnosis and treatment of anemia. GL adherence (GLAD) was analyzed.

Methods

This was a retrospective sample analysis representative for practices and hospitals in Germany. Data on tumor treatments and anemia management was collected from records of cancer patients (pts) with grade ≥ 2 anemia diagnosed between January and June 2021. Definition of diagnosis GLAD score (GLAD-D): 2 points (pt) for full adherence, 1 pt for a lack in differential diagnosis on iron metabolism. 0 pt if differential diagnosis is missing. Treatment GLAD score (GLAD-T): 2 pt for full adherence to GL recommendation in relation to diagnosis. 1 pt for indicated red blood cells (RBC) as only anemia therapy or no therapy in pts with Hb ≥8g/dl. 0 pt for RBC without indication, p.o. iron substitution under inflammatory conditions (CRP>5mg/l) or vitamin B12 or folate deficiency without substitution.

Results

Data from 1046 pts (311 BC, 371 GC, 260 LC, 104 ML) were collected from 143 centers. Hb-values at diagnosis of anemia were 8-10 g/dl in 899 (85.9%) pts, 6-8g/dl in 135 (12.9%) and <6g/dl (1.2%) in 12 pts. 456 pts were treated with RBC (43.6%), 198 (18.9%) with iron substitution, 106 (10.1%) with ESA and 60 (5.7%) with vitamin B12. 60.6% of the pts with iron substitution were treated i.v. and 39.4% p.o. 37.5% of pts with RBC had no indication in the sense of the restrictive RBC policy recommended by the GLs. GLAD was poor in diagnosis and treatment: GLAD-D was 2 pt in 310 pts (29.6%) of pts, 1 pt at 168 (16.1%) and 0 pt in 568 (54.3%) pts. GLAD-T was 2 pt in 270 pts (25.8%), 1 pt in 310 (29.6%) and 0 pt in 466 (44.6%). Higher GLAD-D correlated significantly to a higher GLAD-T (τ B 0.262, p<0.001). Full GLAD-T (2 pt) was significantly associated with a greater Hb increase (p<0.001) at 28 days (10.2 vs. 9.7 g/dl) and at 2 months (10.4 vs 9.9 g/dl).

Conclusions

GLAD is insufficient in Germany, especially concerning liberal transfusion policy and the lack of differential diagnostics of iron metabolism. Pts with anemia management as per GL had a significantly greater Hb-increase.

Clinical trial identification

NCT05190263, AIO-SUP-0121.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien-gGmbH on behalf of the Working Groups Medical Oncology (AIO) and Supportive Care (AGSMO) of the German Cancer Society (DKG).

Funding

The study was supported by unrestricted grants from Pharmacosmos to the AIO-Studien-gGmbH of the German Cancer Society, AIO-SUP-01121. The funding source did not have any access to the data and was not involved in data analysis.

Disclosure

H. Link: Financial Interests, Personal, Advisory Board: Pharmacosmos, Servier Deutschland GmbH, SIGAL SMS GmbH, Takeda, Hogg Robinson Germany, Teva, Apogepha, G1 Therapeutics; Financial Interests, Personal, Expert Testimony: Samsung Bioepis; Financial Interests, Personal, Invited Speaker: Teva, Vision Plus Mailand, MMF GmbH, Teva - Xcenda; Financial Interests, Personal, Ownership Interest, onkopti.de: Onkodin GmbH; Financial Interests, Institutional, Invited Speaker, Onkodin GmbH, onchemo.com: Viatris; Financial Interests, Institutional, Research Grant, Study with German Cancer Society: AMGEN; Financial Interests, Institutional, Research Grant, Grant to German Cancer Society: Pharmacosmos; Non-Financial Interests, Project Lead, Digitized Oncological Treatment Protocols - onkopti.de, onchemo.com: Onkodin GmbH; Other, Expert Testimony: Ethics Committee at the Rhineland-Palatinate Medical Association, Mainz. M. Kerkmann: Financial Interests, Personal, Full or part-time Employment: MMF GmbH; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Amgen, Bristol-Myers Squibb, Janssen-Cilag, Pharmacosmos, MSD, Takeda; Non-Financial Interests, Member: Working Group Medical Oncology (AIO) of the German Cancer Society (DKG), Working Group Supportive Care (AGSMO) of the German Cancer Society (DKG), German Cancer Society (DKG). L. Holtmann: Financial Interests, Personal, Full or part-time Employment: MMf GmbH; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Bristol Myers-Squibb, Janssen-Cilag, MSD, Pharmacosmos, Roche, Takeda.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.